Deeply focus on industrial policies, global pharmaceutical research and development trends and investment and financing trends, comprehensively discuss the development trend of global pharmaceutical innovation, and jointly discuss the new development of biomedical investment cooperation. On September 27, 2020, the 5th China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "Venture Capital Conference") kicked off in Suzhou Industrial Park. Simcere Pharmaceutical and other well-known pharmaceutical companies, pharmaceutical industry experts, investment experts and other experts participated in the conference.
　　At the meeting, Ren Jinsheng, annual president of China Pharmaceutical Innovation Promotion Association and chairman and CEO of Simcere Pharmaceutical, delivered a speech on behalf of the organizers: "At present, China's biopharmaceutical industry faces many uncertainties and an unprecedented series of challenges, and the next five years will be a key opportunity period for the transformation and upgrading of China's biopharmaceutical.
　　Patients regardless of race, no national boundaries, China's pharmaceutical innovation and investment should not only pay attention to the internal circulation of market and resource elements, but also make good use of Chinese elements and China's advantages, proactive, bold, greater efforts to promote foreign exchanges and cooperation, with openness and cooperation to promote higher levels of innovation and investment. Let us firmly remember the lofty mission of helping patients, adhere to open innovation, and contribute China's strength to innovation and investment in the global life sciences sector."Song Ruilin, Executive President of China Pharmaceutical Innovation Promotion Association, presided over the opening ceremony of the conference. Ren Jinsheng, Chairman and CEO of China Pharmaceutical Innovation Promotion Association, Li Li, CEO of Hong Kong Stock Exchange Group, and Li Yaping, Deputy secretary of Suzhou Municipal Party Committee and Mayor of Suzhou, delivered a speech on behalf of the organizers. Warmly welcome leaders, experts, investment community and colleagues in the medical industry Come and wish the conference a complete success. Chen Deming, former Minister of Commerce and President of the China Association of Enterprises with Foreign Investment, and Shang Fulin, Director of the Committee of Economy of the CPPCC National Committee and former Chairman of the China Banking Regulatory Commission addressed the opening ceremony.
　　Big data and omics driven medicine bring new challengesProfessor Wang Yongjun, President of Beijing Tiantan Hospital Affiliated to Capital Medical University, delivered a speech entitled "Innovative Drug Development from the perspective of Clinical Research", talking about the health industry driven by big data and omics. Professor Wang Yongjun said that after the arrival of high-definition medicine, big data and omics driven medicine have brought new challenges to new drug research and development and clinical medicine. From the perspective of industrial structure, the industrial structure promoted by omics and clinical big data is roughly divided into five categories, including health big data, medical blockchain, medical artificial intelligence companies, reverse drug research and development, etc., which are all driven by big data.
　　He also mentioned: "On July 30 this year, we promoted the launch of the innovative neuroprotection drug Edaravone dextrocamphorol Injection concentrated solution (trade name: Xianbixin ®), which is the result of ten years of hard work with Xiansheng. This takes advantage of the powerful clinical evaluation capabilities of the National Center ARO."Discuss the development trend of global pharmaceutical innovationIn the discussion session of the "Global Pharmaceutical Innovation Development Trend", He Ruyi, former chief scientist of the CFDA Pharmaceutical Approval Center, said: "Although China has developed innovative drugs very well in recent years, it is necessary to recognize the gap with the international advanced level. Personally, I feel that it is easy to achieve breakthroughs. The focus of new drug research and development is biological drugs, and the second is improved new drugs, which is our strength. Other new technologies, such as gene therapy, will also make breakthroughs in the next few years and will catch up with the world's advanced level."And how to pay for valuable innovation is the focus of attention of Conway, executive president of RDPAC, "In the national health insurance fund expenditure, if compared with other advanced countries, the structure of innovative drugs is still less, probably less than 10% of innovative drugs such truly patented products, while developed countries at least 50% to 60%." We can also see that the state is also carrying out industrial adjustment and policy guidance, and increasing valuable innovation investment. However, the medical insurance fund is limited, and the industry needs to work together to explore diversified payment and commercial insurance in the future."Jiang Jiandong, president of the 2017-2018 China Pharmaceutical Promotion Association and director of the Institute of Maternology of the Chinese Academy of Medical Sciences, said: "The new coronavirus epidemic has changed many views of the industry in the past, for example, it was believed that infectious diseases such as tuberculosis, polio, AIDS and hepatitis B were basically well controlled, but the sudden new coronavirus epidemic has made the world a big impact Both vaccine research and drug research are in the spotlight, which suggests that there are actually a lot of infectious diseases that we don't know about that need to be better controlled."Li Ning, CEO of Junshi Biology, believes that the future of innovative drug companies is bright, the road is tortuous, how to be able to unify this road in terms of government policy and talent training, collaboration, which is the fundamental elements of the survival of innovative drug companies, but also China's pharmaceutical innovation must be thought through.
　　President Song Ruilin recognized their views and concluded: "The study of global pharmaceutical innovation trends should have its own characteristics, in line with China's national conditions, but at the same time can not lag behind the development of the whole world." "How innovative companies can be based in China and look to the world is a matter of focusing on current clinical needs, world needs, and global development."In addition, Ren Jinsheng, chairman and CEO of Simcere Pharmaceutical, mentioned at the conference that let us firmly remember the lofty mission of helping patients, adhere to open innovation, and contribute China's strength to the innovation and investment in the global life science field. In this regard, Simcere Pharmaceutical will use practical actions to fulfill their mission.